
CLINICIANS
ARE OUR HEROES.
THE VALUE OF ALL4CURE.
All4Cure understands the demands on today's oncologists in staying at the forefront of myeloma care. We've lived it. Our platform is designed to be your partner, amplifying your expertise with aggregated knowledge and advanced analytics, empowering you to deliver the best possible care for your patients.
Unlock the power of collaborative knowledge. All4Cure is your ally, complementing and super-powering your expertise.
Expert-Level Care for All
We empower general oncologists to deliver expert-level care for their patients with multiple myeloma without needing to be myeloma subspecialists themselves.
Clinical Trial Access
We precisely identify patients eligible for clinical trials. Participation in All4Cure includes ongoing monitoring of all trials your patients may qualify for.
Patient Records
At-A-Glance
Focus on What Matters Most
All4Cure’s patient dashboards allow oncologists to deliver better care in less time, grasping a patient's complete medical history in seconds.
Spend less time on data aggregation and more time on patient care, while contributing to the development of cures for multiple myeloma.


Simplifying Complex Treatment Journeys.
Multiple myeloma is highly heterogeneous, and standard protocols often fall short for atypical cases-making treatment decisions challenging without subspecialty support.
All4Cure is here to change that.
All4Cure’s collaborative platform connects you with a global network of myeloma experts, researchers, and patients, providing real-time insights and personalized recommendations. By sharing de-identified clinical data, you gain access to the latest evidence and expert consensus, empowering you to deliver precise, individualized care for every patient.
All4Cure's Clinical Pathway.
All4Cure's Value-Based Clinical Pathway for Multiple Myeloma serves as an accessible resource for clinicians and patients, complementing the personalized care provided by oncologists familiar with individual patient circumstances.
The pathway aims to provide suggestions for optimal care for newly diagnosed patients. The Value-Based Clinical Pathway for Multiple Myeloma™ is updated as new data becomes available.
Download a copy of our Value-Based Clinical Pathway below.
How Our Platform Works.
All4Cure seamlessly empowers you with data-driven insights and a world-class network.
Personalized
Insights, Delivered
Receive concise data visualizations, summaries, and curated insights about treatment journeys.
Consult and Collaborate
Leverage the All4Cure network to connect with myeloma specialists on complex cases.
Patient Data Aggregation
Our AI-powered engine securely gathers relevant patient data (with patient permission).
Secure
Account Setup
A quick, easy and secure account setup process. There are no complicated IT integrations.

A Force Multiplier.
Amidst over 200 kinds of cancer and an ever-growing flood of information, All4Cure is centered on a key challenge: how can general oncologists deliver expert-level care across all cancers? All4Cure acts as a powerful amplifier for clinicians by consolidating disparate data, providing access to a global network of experts, and facilitating data-driven insights that enhance their treatment decisions. By empowering clinicians with collective knowledge from the myeloma community, All4Cure helps them provide specialized care, starting with multiple myeloma. No patient should be alone, and neither should their clinicians.
Oncologist Spotlight:
Dr. Tara Graff
All4Cure is proud to spotlight Dr. Tara Graff, a hematologist/oncologist at Mission Cancer + Blood in Des Moines, Iowa, and a passionate advocate for patients with hematological malignancies.
Dr. Graff’s pioneering development of protocols for outpatient administration of bispecific T cell engaging (BiTE) and CAR-T therapies has made these advanced treatments more accessible.
She also leads a community-based clinical trial program, partnering with organizations like the Iowa-Wide Oncology Research Association to bring cutting-edge therapies to underserved patients locally. Her work ensures patients can receive innovative care close to home while contributing to advancements in cancer research.
We celebrate Dr. Graff's dedication, leadership, and innovative contributions to advancing care for patients with hematological malignancies.